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Objectives: 
 To describe the morphology of bone marrow aspirates in acute myeloid leukemia(AML).  
 To correlate the bone marrow morphology with results of cytogenetic analysis and mutation 
screening.  
 To categorize AML using both the French-American-British(FAB) and the World Health 
Organization(WHO) classification systems  
 
Methods: 
 A total of 156 newly diagnosed cases of AML presenting to Christian Medical College, Vellore 
over a period of one year from January 2015 to December 2015 were included in this study.  
 Bone marrow aspirate smears and peripheral blood smears of 156 patients with AML were 
studied and findings such as differential count, blast lineage assessment and assessment of 
dysplasia were noted.  
 Laboratory haematological parameters such as haemoglobin, platelet count and total leucocyte 
count were assessed for all the patients.  
 Cytogenetic analysis using karyotyping was carried out in 142 of the 156 patients.  
 Mutation screening for NPM1, FLT3-ITD and FLT3-TKD genes was carried out for 47 patients.  
 
Results 
 The median age of the patients was 32 years (range: 7 months to 76 years).  
 Using the FAB classification, the most common subtype was AML-M2(37%) followed by 
AML-M1(21%). AMl-M6(1%) was the least common subtype.  
 Cytogenetic analysis –  
 
 Abnormal karyotypes were seen 62% of our patients.  
 (15;17)(q22;q12) was the most common recurrent genetic abnormality observed. 
t(8;21)(q22;q22.1) was seen in 8% patient. Rest of the abnormalities were seen in 
~1-2% of patients.  
 Other common cytogenetic abnormalities observed were 
 Trisomy 8 – 9% 
 Monosomy 7 – 8% 
 Complex karyotypes (3 or more abnormalities) – 13% 
 Monosomal karyotypes – 9%.  
 Mutation screening –  
 
 NPM1 mutation was seen in 47% (22/47) patients, and in 74% (20/27) patients 
with normal karyotype.  
 FLT3-ITD mutations were seen in 19% (9/47) of patients.  
 FLT3-TKDmutations were seen in 17% (8/47) of patients.  
 Concomitant NPM1 and FLT3 mutations were concomitantly seen in 28% 
(13/47) of patients 
 
 
 Using the 2016 revision to the WHO classification of AML–  
 AML with recurrent genetic abnormalities (AML-RGA) accounted for 42% of 
patients. 
 AML, not otherwise specified (AML, NOS) accounted for 37% of patients.  
 AML with myelodysplasia-related changes(AML-MRC) accounted for 21% of 
patients  
 AML-MRC based only on morphological evidence of dysplasia -   
23%. 
 AML-MRC based on morphology and /or cytogenetic changes -  
77%. 
 
 Risk classification according to modified European LeukemiaNet(ELN) classification system –  
 
 Favorable risk profile was seen in 37% of patients.  
 Intermediate risk profile was seen in 38% of patients 
 Adverse risk profile was seen in 25% of patients.    
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